Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Stomach Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Advanced and Metastatic Urothelial Cancer 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × futibatinib × Clear all
NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Taiho Oncology, Inc.

Phase 2 Terminated
64 enrolled 21 charts
Breast

Breast Neoplasms

NCT02052778 2025-03-27

A Study of TAS-120 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
407 enrolled 45 charts 1 FDA
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡